Oryzon Genomics S.A. (ORN)
XSTU
Closed
Sep 25, 2026
Day's Range
2.7252 wk Range
2.63Overview - ORN - Oryzon Genomics S.A.
Key Statistics
Valuation
Enterprise Value
193.68M
P/E (Trailing)
‪-69.44‬
EV / EBITDA
‪-40.28‬
Profitability
Return on Assets
‪-1.80%‬
Return on Equity
‪-2.21%‬
Ownership
Shares Outstanding
81.95M
Price stats
50-Day Avg
‪3.15‬
200-Day Avg
‪2.94‬
Market Cap - ORN - Oryzon Genomics S.A.
Peers - ORN - Oryzon Genomics S.A.
Peer Comparison
Compared with companies in Biotechnology listed on XSTU.
- ORNXSTUOryzon Genomics S.A.214.40MMarket Cap-6.86%52-week change-69.45P/E (Trailing)—Profit Margin
- 6IBXSTUInnovent Biologics Inc.14.71BMarket Cap+6.26%52-week change—P/E (Trailing)‪86.53%‬Profit Margin
- 4KBXSTUKrystal Biotech, Inc.8.99BMarket Cap+52.99%52-week change43.02P/E (Trailing)‪54.81%‬Profit Margin
- 19XXSTUAxsome Therapeutics Inc.7.98BMarket Cap+41.36%52-week change-46.29P/E (Trailing)‪92.56%‬Profit Margin
- 2X10XSTUAbivax SA Sponsored ADR7.19BMarket Cap+12.50%52-week change-16.56P/E (Trailing)‪0.00%‬Profit Margin
- 30JXSTUIDEAYA Biosciences Inc.3.10BMarket Cap+29.17%52-week change-25.15P/E (Trailing)‪-74.75%‬Profit Margin
- BSFAXSTUAni Pharmaceuticals, Inc.1.49BMarket Cap-19.23%52-week change16.21P/E (Trailing)‪11.07%‬Profit Margin
Profile Summary - ORN - Oryzon Genomics S.A.
About
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, it targets lysine-specific demethylase 1 (LSD1), a…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
